Drug Comparison
For educational purposes only — a decision-support tool, not a substitute for clinical judgment.
Side-by-side rubric across 96 psychiatric medications. Every rating traces to a verbatim primary-source quote — click any cell to see it.
How to read this tool ▾
Rating scale
– Favorable / lower than class baseline
± Minimal / equivocal
+ Low / uncommon
++ Moderate / common
+++ High / very common
++++ Very high / class-outlier
Frequency vs severity
F = frequency, S = severity. Each gets its own pill colored on the same traffic-light scale: green → blue → yellow → orange → red. Click any cell for incidence percentages and NNH.
Evidence tier
A Network meta-analysis / RCT / FDA label
B Cohort / registry / pooled label data
C Expert review / textbook / case series
Sourcing
Click any cell to see the verbatim source quote and citation. Missing data shows n/a.
Data depth
++ Graded — frequency + severity, primary-source traces
+ FDA label — §6 frequency only (dashed border). Click for sub-types.
Blank — not yet checked (not “absent”)
–±++++++++++ABCF = frequency · S = severity · Dashed border = FDA label only · Click cell for details
1 drug selected — Lurasidone(click to collapse)
1/4 selected
Lurasidone
Latuda
Second-Generation Antipsychotic
FDA-approved indications
- Schizophrenia (adults; adolescents 13–17 years)
- Bipolar I depression — monotherapy (adults; pediatric 10–17 years)
- Bipolar I depression — adjunct to lithium/valproate (adults)
Off-label uses
- Treatment-resistant depression (adjunct)
- Schizoaffective disorder
Half-life18 hours
Decision GuideWhen to pick each / when to consider an alternative
Lurasidone
Consider when
- Metabolic risk prohibits other SGAs — lowest glucose P-score (0.09) in Huhn NMA; favorable weight and lipid profile
- Bipolar depression (mono or adjunct) — FDA-approved for both monotherapy and adjunct to lithium/valproate in bipolar I depression
- QTc prolongation risk — negative QTc point estimate (−1.18 ms Leucht); among safest SGAs for cardiac patients
- Prolactin-sensitive patient — low transient prolactin elevation; favorable vs risperidone/paliperidone
- +1 more
Consider an alternative when
- Inconsistent food intake — must take with ≥350 kcal meal; bioavailability ~3× lower fasting; adherence barrier
- Akathisia is a top priority — highest akathisia RR among SGAs in Huhn 2019 (RR 3.93); leading tolerability concern
- Severe nausea or GI sensitivity — nausea 10% vs 5% placebo; rates rise with dose; may limit titration
- On strong CYP3A4 inhibitor or inducer — contraindicated with strong inhibitors (ketoconazole); dose limits with moderate inhibitors
- +1 more
| Axis | Lurasidone SGA |
|---|---|
| Boxed Warnings | |
Suicidality (boxed warning) | |
Agranulocytosis / severe neutropenia | |
Cerebrovascular events (elderly w/ dementia) | |
Neuroleptic malignant syndrome (NMS) | |
| CNS | |
Sedation / somnolence | |
Activation / insomnia | |
Akathisia / EPS | |
Tardive dyskinesia | |
Seizure risk | |
| Metabolic | |
Weight gain | |
Metabolic (glucose / lipids) | |
| Endocrine | |
Prolactin elevation | |
| Autonomic | |
Anticholinergic burden | |
Orthostatic hypotension | |
| Cardiac | |
QTc prolongation | |
| GI | |
Nausea / GI (general) | |
| Sexual | |
Sexual dysfunction | |
| Interactions | |
CYP interactions / DDI profile | |
| Pregnancy | |
Lactation / breastfeeding safety | |